Technology ID
TAB-4553

Monoclonal Anti-mouse and Anti-human TL 1A Antibodies for Diagnostic and Therapeutic Utilization

E-Numbers
E-073-2011-0
Lead Inventor
Siegel, Richard
Co-Inventors
Meylan, Francoise (NIAMS)
Song, Yun-Jeong (ImmuneOncia Therapeutics, Inc)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Immunology
Development Stages
Pre-Clinical (in vitro)
Research Products
Antibodies
Lead IC
NIAMS
ICs
NIAMS

This technology includes antibodies against TL 1A for the inhibition of TL 1A-DR3 interactions for the diagnosis and treatment of various autoimmune diseases. Through the use of our developed hamster anti-mouse and mouse anti-human monoclonal antibodies, we’ve demonstrated that treatment with anti-mouse TL 1A prevented collagen-induced arthritis and TNBS-induced colitis NEED TO UPDATE

Commercial Applications
Compounds developed from this discovery could be used to treat systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type-I diabetes, graft vs. host disease, or any other autoimmune disease with a T-lymphocyte pathophysiology component.

Competitive Advantages
Multiple potential therapeutic and diagnostics uses for a variety of autoimmune diseases.

Request More Info

Licensing Contact:
Knezevic, Vladimir
vlado.knezevic@nih.gov

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.
Date Published